{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:23:32Z","timestamp":1785331412463,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,7,20]],"date-time":"2010-07-20T00:00:00Z","timestamp":1279584000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1038\/sj.bjc.6605798","type":"journal-article","created":{"date-parts":[[2010,7,20]],"date-time":"2010-07-20T21:04:19Z","timestamp":1279659859000},"page":"462-468","source":"Crossref","is-referenced-by-count":47,"title":["Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer"],"prefix":"10.1038","volume":"103","author":[{"given":"N M","family":"Corcoran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C M","family":"Hovens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A J","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,7,20]]},"reference":[{"key":"BF6605798_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-59745-241-0_1","volume":"467","author":"Z Ahmed","year":"2009","unstructured":"Ahmed Z, Bicknell R (2009) Angiogenic signalling pathways. Methods Mol Biol 467: 3\u201324","journal-title":"Methods Mol Biol"},{"key":"BF6605798_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2174\/1874467210902020161","volume":"2","author":"JB Aragon-Ching","year":"2009","unstructured":"Aragon-Ching JB, Dahut WL (2009) VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol 2: 161\u2013168","journal-title":"Curr Mol Pharmacol"},{"key":"BF6605798_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1023\/B:CACO.0000024212.66334.26","volume":"15","author":"PD Baade","year":"2004","unstructured":"Baade PD, Coory MD, Aitken JF (2004) International trends in prostate-cancer mortality: the decrease is continuing and spreading. Cancer Causes Control 15: 237\u2013241","journal-title":"Cancer Causes Control"},{"key":"BF6605798_CR4","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592\u2013603","journal-title":"Nat Rev Cancer"},{"key":"BF6605798_CR5","first-page":"2533","volume":"61","author":"RA Bok","year":"2001","unstructured":"Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ (2001) Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 61: 2533\u20132536","journal-title":"Cancer Res"},{"key":"BF6605798_CR6","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/annonc\/mdm554","volume":"19","author":"KN Chi","year":"2008","unstructured":"Chi KN, Ellard SL, Hotte SJ, Czaykowski P, Moore M, Ruether JD, Schell AJ, Taylor S, Hansen C, Gauthier I, Walsh W, Seymour L (2008) A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 19: 746\u2013751","journal-title":"Ann Oncol"},{"key":"BF6605798_CR7","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jocn.2010.04.020","volume":"17","author":"NM Corcoran","year":"2010","unstructured":"Corcoran NM, Martin D, Hutter-Paier B, Windisch M, Nguyen T, Nheu L, Sundstrom LE, Costello AJ, Hovens CM (2010) Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer\u2032s disease model. J Clin Neurosci 17: 1025\u20131033","journal-title":"J Clin Neurosci"},{"key":"BF6605798_CR8","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1097\/01.ju.0000092859.16817.8e","volume":"171","author":"NM Corcoran","year":"2004","unstructured":"Corcoran NM, Najdovska M, Costello AJ (2004) Inorganic selenium retards progression of experimental hormone refractory prostate cancer. J Urol 171: 907\u2013910","journal-title":"J Urol"},{"key":"BF6605798_CR9","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.juro.2006.07.002","volume":"176","author":"TJ Daskivich","year":"2006","unstructured":"Daskivich TJ, Regan MM, Oh WK (2006) Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. J Urol 176: 1927\u20131937","journal-title":"J Urol"},{"key":"BF6605798_CR10","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/annonc\/mdp111","volume":"20","author":"M Dror Michaelson","year":"2009","unstructured":"Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW, Smith MR (2009) Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 20: 913\u2013920","journal-title":"Ann Oncol"},{"key":"BF6605798_CR11","first-page":"1388","volume":"60","author":"A Eberhard","year":"2000","unstructured":"Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60: 1388\u20131393","journal-title":"Cancer Res"},{"key":"BF6605798_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrc2403","volume":"8","author":"LM Ellis","year":"2008","unstructured":"Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579\u2013591","journal-title":"Nat Rev Cancer"},{"key":"BF6605798_CR13","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182\u20131186","journal-title":"N Engl J Med"},{"key":"BF6605798_CR14","first-page":"1932","volume":"7","author":"DJ George","year":"2001","unstructured":"George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, Kantoff PW (2001) Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7: 1932\u20131936","journal-title":"Clin Cancer Res"},{"key":"BF6605798_CR15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/ncpuro1188","volume":"5","author":"HD Georgiou","year":"2008","unstructured":"Georgiou HD, Namdarian B, Corcoran NM, Costello AJ, Hovens CM (2008) Circulating endothelial cells as biomarkers of prostate cancer. Nat Clin Pract Urol 5: 445\u2013454","journal-title":"Nat Clin Pract Urol"},{"key":"BF6605798_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s00428-005-0075-3","volume":"448","author":"K Gravdal","year":"2006","unstructured":"Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA (2006) Expression of bFGF\/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Arch 448: 68\u201374","journal-title":"Virchows Arch"},{"key":"BF6605798_CR17","doi-asserted-by":"publisher","first-page":"4708","DOI":"10.1158\/0008-5472.CAN-08-4417","volume":"69","author":"K Gravdal","year":"2009","unstructured":"Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA (2009) Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Res 69: 4708\u20134715","journal-title":"Cancer Res"},{"key":"BF6605798_CR18","first-page":"3791","volume":"20","author":"OJ Halvorsen","year":"2000","unstructured":"Halvorsen OJ, Haukaas S, Hoisaeter PA, Akslen LA (2000) Independent prognostic importance of microvessel density in clinically localized prostate cancer. Anticancer Res 20: 3791\u20133799","journal-title":"Anticancer Res"},{"key":"BF6605798_CR19","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/jnci\/94.12.883","volume":"94","author":"L Hlatky","year":"2002","unstructured":"Hlatky L, Hahnfeldt P, Folkman J (2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn\u2019t tell us. J Natl Cancer Inst 94: 883\u2013893","journal-title":"J Natl Cancer Inst"},{"key":"BF6605798_CR20","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nrclinonc.2009.130","volume":"6","author":"SP Ivy","year":"2009","unstructured":"Ivy SP, Wick JY, Kaufman BM (2009) An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 6: 569\u2013579","journal-title":"Nat Rev Clin Oncol"},{"key":"BF6605798_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225\u2013249","journal-title":"CA Cancer J Clin"},{"key":"BF6605798_CR22","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1093\/jnci\/djj211","volume":"98","author":"SJ Kim","year":"2006","unstructured":"Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis C, Mathew P, Wang X, Do KA, Fan D, Fidler IJ (2006) Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 98: 783\u2013793","journal-title":"J Natl Cancer Inst"},{"key":"BF6605798_CR23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.canlet.2008.10.034","volume":"276","author":"YS Kim","year":"2009","unstructured":"Kim YS, Ahn KH, Kim SY, Jeong JW (2009) Okadaic acid promotes angiogenesis via activation of hypoxia-inducible factor-1. Cancer Lett 276: 102\u2013108","journal-title":"Cancer Lett"},{"key":"BF6605798_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.chroma.2007.12.065","volume":"1181","author":"CY Kuo","year":"2008","unstructured":"Kuo CY, Jiang SJ (2008) Determination of selenium and tellurium compounds in biological samples by ion chromatography dynamic reaction cell inductively coupled plasma mass spectrometry. J Chromatogr A 1181: 60\u201366","journal-title":"J Chromatogr A"},{"key":"BF6605798_CR25","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.bbagen.2009.04.013","volume":"1790","author":"J Lu","year":"2009","unstructured":"Lu J, Berndt C, Holmgren A (2009) Metabolism of selenium compounds catalyzed by the mammalian selenoprotein thioredoxin reductase. Biochim Biophys Acta 1790: 1513\u20131519","journal-title":"Biochim Biophys Acta"},{"key":"BF6605798_CR26","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.1200\/JCO.2008.20.8876","volume":"27","author":"LA Mucci","year":"2009","unstructured":"Mucci LA, Powolny A, Giovannucci E, Liao Z, Kenfield SA, Shen R, Stampfer MJ, Clinton SK (2009) Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 27: 5627\u20135633","journal-title":"J Clin Oncol"},{"key":"BF6605798_CR27","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1200\/JCO.2009.25.4524","volume":"28","author":"YM Ning","year":"2010","unstructured":"Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL (2010) Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28: 2070\u20132076","journal-title":"J Clin Oncol"},{"key":"BF6605798_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1046\/j.1525-1411.2001.32007.x","volume":"3","author":"DM Reese","year":"2001","unstructured":"Reese DM, Fratesi P, Corry M, Novotny W, Holmgren E, Small E (2001) A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate J 3: 65\u201370","journal-title":"Prostate J"},{"key":"BF6605798_CR29","first-page":"3651","volume":"27","author":"K Revelos","year":"2007","unstructured":"Revelos K, Petraki C, Scorilas A, Stefanakis S, Malovrouvas D, Alevizopoulos N, Kanellis G, Halapas A, Koutsilieris M (2007) Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res 27: 3651\u20133660","journal-title":"Anticancer Res"},{"key":"BF6605798_CR30","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26: 1148\u20131159","journal-title":"J Clin Oncol"},{"key":"BF6605798_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/(SICI)1097-0045(20000101)42:1<26::AID-PROS4>3.0.CO;2-6","volume":"42","author":"D Strohmeyer","year":"2000","unstructured":"Strohmeyer D, Rossing C, Strauss F, Bauerfeind A, Kaufmann O, Loening S (2000) Tumor angiogenesis is associated with progression after radical prostatectomy in pT2\/pT3 prostate cancer. Prostate 42: 26\u201333","journal-title":"Prostate"},{"key":"BF6605798_CR32","first-page":"302","volume":"10","author":"N Weidner","year":"1993","unstructured":"Weidner N (1993) Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol 10: 302\u2013313","journal-title":"Semin Diagn Pathol"},{"key":"BF6605798_CR33","unstructured":"Weidner N, Folkman J (1996) Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol 167\u2013190"},{"key":"BF6605798_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199101033240101","volume":"324","author":"N Weidner","year":"1991","unstructured":"Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis\u2014correlation in invasive breast carcinoma. N Engl J Med 324: 1\u20138","journal-title":"N Engl J Med"},{"key":"BF6605798_CR35","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/sj.onc.1210663","volume":"27","author":"F Yang","year":"2008","unstructured":"Yang F, Strand DW, Rowley DR (2008) Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma. Oncogene 27: 450\u2013459","journal-title":"Oncogene"},{"key":"BF6605798_CR36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1158\/1078-0432.CCR-06-0774","volume":"13","author":"X Yao","year":"2007","unstructured":"Yao X, Qian CN, Zhang ZF, Tan MH, Kort EJ, Yang XJ, Resau JH, Teh BT (2007) Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications. Clin Cancer Res 13: 161\u2013169","journal-title":"Clin Cancer Res"},{"key":"BF6605798_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10456-004-1027-2","volume":"7","author":"MR Young","year":"2004","unstructured":"Young MR (2004) Tumor-derived prostaglandin E2 and transforming growth factor-beta stimulate endothelial cell motility through inhibition of protein phosphatase-2A and involvement of PTEN and phosphatidylinositide 3-kinase. Angiogenesis 7: 123\u2013131","journal-title":"Angiogenesis"},{"key":"BF6605798_CR38","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ijc.10491","volume":"100","author":"MR Young","year":"2002","unstructured":"Young MR, Kolesiak K, Meisinger J (2002) Protein phosphatase-2A regulates endothelial cell motility and both the phosphorylation and the stability of focal adhesion complexes. Int J Cancer 100: 276\u2013282","journal-title":"Int J Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6605798.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605798","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605798.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:46:13Z","timestamp":1684413973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6605798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,20]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["BF6605798"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6605798","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,20]]}}}